SREBF1 and metabolic dysfunction-associated steatotic liver disease: Consistent with our data, in experimental MASLD, dapagliflozin reduced DNL by upregulating nuclear receptors farnesoid X receptor/small heterodimer partner (FXR/SHP) and downregulating liver X receptor alpha (LXRα)/SREBP-1c in the liver.